Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Brief report: Psychopharmacology of autism spectrum disorders

  • 125 Accesses

  • 11 Citations

Abstract

The purpose of this paper is to review briefly recent findings on the efficacy of psychopharmacological interventions in autism spectrum disorder, point out gaps in our current knowledge of the effects of specific drug classes, and suggest both general and specific research directions for the future. For a more comprehensive review of drug studies in autism, readers are directed toward McDougle, Price, and Volkmar (1994).

This is a preview of subscription content, log in to check access.

References

  1. Aman, M. G., & Kern, R. A. (1989). Review of fenfluramine in the treatment of the developmental disabilities.Journal of the American Academy of Child and Adolescent Psychiatry, 28, 549–565.

  2. Campbell, M., Anderson, L. T., Meier, M., Cohen, I. L., Small, A. M., Samit, C., & Sachar, E. J. (1978). A comparison of halperidol and behavior therapy and their interaction in autistic children.Journal of the American Academy of Child Psychiatry, 17, 640–655.

  3. Campbell, M., Anderson, L., Small, A., Adams, P., Gonzalez, N., & Ernst, M. (1993). Naltrexone in autistic children: Behavioral symptoms and attentional learning.Journal of the American Academy of Child and Adolescent Psychiatry, 32, 1283–1291.

  4. Chamberlain, R. S., & Herman, B. H. (1990). A novel biochemical model linking dysfunctions in brain melatonin, proopiomelanocortin peptides, and serotonin in autism.Biological Psychiatry, 28, 773–793.

  5. Cook, E. H. J., Rowlett, R., Jaselskis, C., & Leventhal, B. L. (1992). Fluoxetine treatment of children and adults with autistic disorder and mental retardation.Journal of the American Academy of Child and Adolescent Psychiatry, 31, 739–745.

  6. Gillberg, C. (1995). Endogenous opioids and opiate antagonists in autism: Brief review of empirical findings and implications for clinicians.Developmental Medicine and Child Neurology, 37, 239–245.

  7. Gordon, C. T., Rapoport, J. L., Hamburger, S. D., State, R. C., & Mannheim, G. B. (1992). Differential response of seven subjects with autistic disorder to clomipramine and desipramine.American Journal of Psychiatry, 149, 363–366.

  8. Lewis, M. H., Bodfish, J. W., Powell, S. B., & Golden, R. N. (1995). Clomipramine treatment for repetitive movement disorders in mental retardation: A double-blind comparison with placebo.American Journal on Mental Retardation, 100, 299–312.

  9. Lewis, M. H., Gluck, J. P., Bodfish, J. W., Beauchamp, A. J., Beauchamp, A. J., & Mailman, R. B. (in press). Neurobiological basis of stereotyped movement disorder in animals and humans. In R. L. Sprague & K. M. Newell (Eds.),Stereotypy: Brain behavior relationships. Washington, DC:American Psychological Association.

  10. McDougle, C. J., Price, L. H., & Volkmar, F. R. (1994). Recent advances in the pharmacotherapy of autism and related conditions.Child and Adolescent Psychiatric Clinics of North America, 3, 71–89.

  11. McDougle, C. J., Price, L. H., Volkmar, F. R., Goodman, W. K., Ward-O'Brien, D., Nielsen, J., Bregman, J., & Cohen, D. J. (1992). Clomipramine in autism: Preliminary evidence of efficacy.Journal of the American Academy of Child and Adolescent Psychiatry, 31, 746–750.

Download references

Author information

Correspondence to Mark H. Lewis.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Lewis, M.H. Brief report: Psychopharmacology of autism spectrum disorders. J Autism Dev Disord 26, 231–235 (1996). https://doi.org/10.1007/BF02172018

Download citation

Keywords

  • Autism Spectrum Disorder
  • Current Knowledge
  • Spectrum Disorder
  • Drug Study
  • School Psychology